Evidence map›Paper›PMID 36948845›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Progress on the research of liver diseases in 2022].

X G Dou, X Y Xu, Y M Nan, L Wei, T Han, Y M Mao, Y Han, H Ren, J D Jia, H Zhuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

X G DouDepartment of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China.
X Y XuDepartment of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
Y M NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
L WeiHepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
T HanTianjin Union Medicine Center, Nankai University Affiliated Hospital, Tianjin 300121, China.
Y M MaoRenji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China.
Y HanDepartment of Gastroenterology, the First Affiliated Hospital, Air Force Medical University, Xi'an 710032, China.
H RenDepartment of Infectious Diseases, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 401336, China.
J D JiaLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
H ZhuangDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver DiseasesLiver NeoplasmsHumansLiver CirrhosisAutoimmune liver diseaseDrug-induced liver injuryFatty liverHepatic fibrosisHepatocellular carcinomaLiver cirrhosisLiver failureLiver transplantationViral hepatitis

Identifiers

PMID36948845
PMCPMC12814298

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.